⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

April 22, 2020Clinical Cancer ResearchOpen Access

Intratumoral Comparison of Nanoparticle Entrapped Docetaxel (CPC634) with Conventional Docetaxel in Patients with Solid Tumors

Florence Atrafi Ruben A.G. van Eerden Marte A.M van Hylckama Vlieg Esther Oomen‐de Hoop Peter de Bruijn Martijn P. Lolkema Adriaan Moelker Cristianne J.F. Rijcken Rob Hanssen Alex Sparreboom Ferry A.L.M. Eskens Ron H.J. Mathijssen Stijn L.W. Koolen

View Full Paper

Ask AI

Bookmark

Share

Abstract

Here, we demonstrated that CPC634 enhanced the intratumoral total docetaxel exposure compared with conventional docetaxel. The lower incidence of neutropenia during CPC634 treatment is presumably related to lower plasma C max of released docetaxel. The unique pharmacokinetic profile of CPC634 nanoparticles has the potential to improve docetaxel treatment. A phase II efficacy trial of CPC634 is currently ongoing.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Atrafi et al. (2020) studied this question.

synapsesocial.com/papers/69dd62fc629747396240cdfa https://doi.org/10.1158/1078-0432.ccr-20-0008

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 related papers. Consider them for comparative context:

1Serial circulating tumour DNA monitoring in first-line advanced NSCLC (COPE): a randomized, two-arm non-comparative phase II trialClinical Cancer Research · Wed,
2DuoBody®-FAPαxDR4 is a novel DR4 agonist that induces potent antitumor activity through FAPα-dependent, DR4-transactivation-mediated apoptosisClinical Cancer Research · Wed,
3Carboplatin Plus Mirvetuximab Soravtansine In Platinum-Sensitive Ovarian Cancer: A Phase 2 Nonrandomized Clinical TrialClinical Cancer Research · Wed,
4Long-Term Outcomes and Biomarker Correlates of a Multi-Institutional Phase II Study of Hypofractionated Proton Beam Therapy for Unresectable Primary Liver TumorsClinical Cancer Research · Wed,
5HexaBody-OX40 promotes antitumor immunity through FcγR crosslinking-independent OX40 agonist activity and enhances effects of PD-1 blocking antibodiesClinical Cancer Research · Wed,

More from Clinical Cancer Research

Radiotherapy combined with serplulimab, and chemotherapy as first-line treatment for metastatic pancreatic adenocarcinoma: a multicenter, single-arm, phase II trialFri,
Anti-TNFR2 antibody BI-1808 induces tumor regression and antitumor T cell immunity through T reg and myeloid cell modulation in patients with solid tumorsThu,
Second- and third-line outcomes after selective RET inhibitor failure in RET fusion-positive metastatic lung cancer: A real-world analysis from the RET-MAP registryWed,
DNA-Based Biomarkers as Predictors of Carboplatin Response in Neoadjuvant Treatment for Hormone Receptor Positive and Triple-Negative Breast CancerWed,
Multi-institutional study evaluating the role of liquid biopsy to determine risk of extraocular disease, therapy response and recurrence in retinoblastomaWed,